Article Text

FRI0301 Prognosis of The Idiopathic Inflammatory Myopathies Associated with Interstitial Lung Disease: Preliminary Analysis of The Registry Remicam
  1. T. Cobo-Ibáñez1,
  2. L. Nuño2,
  3. M.J. García3,
  4. B. Joven4,
  5. V. Maldonado5,
  6. I. Llorente6,
  7. C. Barbadillo7,
  8. P. Garcia De La Peña8,
  9. L. Ruiz9,
  10. H. Moruno10,
  11. R. Almodόvar11,
  12. L. Lojo12,
  13. F.J. Lόpez-Longo13,
  14. on behalf of REMICAM
  1. 1H. Infanta Sofía
  2. 2H. La Paz
  3. 3Instituto de Salud Musculoesquelética
  4. 4H. Doce de Octubre
  5. 5H. Ramόn y Cajal
  6. 6H. la Princesa
  7. 7H. Puerta de Hierro
  8. 8H. Madrid Norte San Chinarro
  9. 9H. Niño Jesús
  10. 10H. Príncipe de Asturias
  11. 11H.F. Alcorcόn
  12. 12H. Infanta Leonor
  13. 13H. Gregorio Marañόn, Madrid, Spain


Background Some studies suggest that clinical subgroups of idiopathic inflammatory myopathies (IIM) and several myositis-specific antibodies (MSAs) could influence the prognosis of IIM with interstitial lung disease (ILD).

Objectives To investigate the prognosis value of different clinical subgroups and of MSAs in a cohort of patients with IIM -associated ILD.

Methods We analyzed patients with IIM-associated ILD included in the multicenter registry REMICAM (1980–2014). We compared prognosis between a) subgroups of IIM: dermatomyositis (DM) vs. polymiosytis (PM) (primary, juvenile, cancer-associated myositis or overlap myositis); and b) absence (−) or presence (+) of anti-Jo1 vs. anti-RO vs. anti-Jo1 and anti-RO. In this preliminary analysis, outcomes were mortality and change between final and initial visit in FVC and DLCO.

Results 478 patients were included in the registry, of which 143 had ILD, 66% PM and 34% DM. The distribution by MSAs was: 56% anti-Jo1-/RO-, 20% anti-Jo1+, 9% anti-RO+ and 15% anti-Jo1+/RO+. There were 52 deaths; the main causes were 32.6% cardiovascular events and 22.4% infections without difference between subgroups of IIM. The probability of survival was 50% to 18.8 years and the mortality rate was 37.7/1000 patient-ys. We did not find differences when we compared survival between subgroups of IIM or we compared by MSAs. FVC seemed to improve more in DM than in PM patients (1.2±5.2vs. 0.5±4.7;p=0.059), but there were no significant changes in DLCO of DM patients or in FVC and DLCO according to MSAs.

Conclusions We did not find prognostic differences in the causes of mortality, mortality rate between subgroups of IIM, or in mortality rate according to MSAs in patients with ILD. In DM patients there was a trend towards a greater improvement of FVC than in PM patients.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.